Mavefund EN
Zoetis Inc logo

Zoetis Inc

ZTS
Letzter Kurs (USD) US$77.02
Marktkapitalisierung (USD) US$31.9b
Kursänderung 12 Monate -50.77%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
Amphastar PAMPH Vergleich Prestige Consumer HealthcarePBH Vergleich TARO PHARMACEUTICAL INDUSTRIES LTDTARO Vergleich IQVIA Holdings IncIQV Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

Zoetis Inc Überblick

Branche: Drug Manufacturers Specialty & Generic

Sektor: Healthcare

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others;

Research-Überblick

Letztes Berichtsdatum 2026-08-06

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Zoetis Inc (ZTS): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
ZTS · NYSE · MIC XNYS
Land
United States
Handelswährung
USD
Branche
Drug Manufacturers Specialty & Generic
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-06
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Zoetis Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 06, 2026

Quarterly result summary

Revenue was $2.5B (reported); EPS was $1.87 (reported).

Revenue $2.5B reported
EPS $1.87 reported
Net income $691M reported

Was sich verändert hat

  • Revenue reported to $2.5B; EPS reported to $1.87.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing 10-Q Aug 06, 2026 SEC filing 8-K Aug 06, 2026 SEC filing 10-Q May 07, 2026 SEC filing 8-K May 07, 2026 Earnings release Earnings release May 07, 2026 SEC filing 10-K Feb 12, 2026 SEC filing 8-K Feb 12, 2026 Earnings release Earnings release Feb 12, 2026 SEC filing 10-Q Nov 04, 2025 SEC filing 8-K Nov 04, 2025 Earnings release Earnings release Nov 04, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 5.00/5
Zoetis Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc
In Drug Manufacturers Specialty & Generic industry , Amphastar P , Prestige Consumer Healthcare , TARO PHARMACEUTICAL INDUSTRIES LTD are companies with high ratings.

Eigenkapitalrendite

Score 4.71/5
Zoetis Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b
Thermo Fishe... TMO US$196.1b

Nettomarge

Score 4.93/5
Zoetis Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b
Thermo Fishe... TMO US$196.1b

Aktienrückkäufe

In Drug Manufacturers Specialty & Generic industry , Amphastar P , Prestige Consumer Healthcare , TARO PHARMACEUTICAL INDUSTRIES LTD are companies with high ratings.

Verschuldung

Score 1.40/5
Zoetis Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including IQVIA Holdings Inc Agilent Technologies Inc Thermo Fisher Scientific Inc have achieved high scores.
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b
Thermo Fishe... TMO US$196.1b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Zoetis Inc logo

Zoetis Inc

US$77.02

US$75.99

-2.2% vs price

US$31.9b

-0.89%

-50.77%